Compounds > ciprofloxacin

ciprofloxacin and deferasirox

ciprofloxacin has been researched along with deferasirox in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cho, HS; Kang, JI; Kim, DM; Kim, HS; Park, CY1
Kim, DM; Neupane, GP1

Reviews

1 review(s) available for ciprofloxacin and deferasirox

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for ciprofloxacin and deferasirox

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.
    The Journal of infection, 2008, Volume: 57, Issue:6

    Topics: Aged; Anti-Bacterial Agents; Benzoates; Ciprofloxacin; Deferasirox; DNA, Bacterial; Drug Therapy, Combination; Female; Hemochromatosis; Humans; Polymerase Chain Reaction; Sepsis; Triazoles; Vibrio Infections; Vibrio vulnificus

2008
In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2010, Volume: 29, Issue:4

    Topics: Anti-Bacterial Agents; Benzoates; Chelating Agents; Ciprofloxacin; Deferasirox; Drug Synergism; Hospitals; Humans; Microbial Sensitivity Tests; Microbial Viability; Republic of Korea; Time Factors; Triazoles; Vibrio Infections; Vibrio vulnificus

2010